Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Dr. Rongxiang Xu Addresses the Ongoing Lawsuit against Nobel Committee and its Continuous False Advertisement of Fake Pluripotent Stem Cell
  • India - English
  • Brazil - Português
  • Latin America - español


News provided by

Dr. Rongxiang Xu

Oct 09, 2013, 09:05 ET

Share this article

Share toX

Share this article

Share toX

LOS ANGELES, Oct. 9, 2013 /PRNewswire/ -- Dr. Rongxiang Xu, the founder of "human body regenerative restoration science" and the patentee of damaged organ regeneration- a top priority claimed in President Obama's 2013 State of the Union, addresses the ongoing lawsuit against Nobel Committee and its continuous false advertisement of fake pluripotent stem cell during the past year since Dr. Xu initially filed his lawsuit against the Academy citing, among other claims, libel and unfair competition.

Continue Reading
Dr. Rongxiang Xu, inventor of "Potential Regenerative Cell" and "Human Regenerative Life Science." (PRNewsFoto/Dr. Rongxiang Xu) (PRNewsFoto/DR. RONGXIANG XU)
Dr. Rongxiang Xu, inventor of "Potential Regenerative Cell" and "Human Regenerative Life Science." (PRNewsFoto/Dr. Rongxiang Xu) (PRNewsFoto/DR. RONGXIANG XU)

Given the winners of 2013 Nobel Prize in Physiology or Medicine were disclosed this week and the Nobel Assembly has not yet made any clarification on its 2012 Prize in Medicine while continuing with its endorsement and false advertisement of fake pluripotent stem cells, Dr. Xu had to come out and tell the public why he sued the Nobel Assembly in 2012 and the progress of the lawsuit.

On October 8, 2012, The Nobel Assembly awarded the Nobel Prize in Physiology or Medicine to Shinya Yamanaka and another expert in nuclear transfer for artificially creating the pluripotency of human somatic cells. In the awarding press release and advertising documentary, the Nobel Assembly stated clearly that the prize winner successfully converted somatic cells into pluripotent stem cells by reprogramming genes. But the winner himself did not acknowledge he produced pluripotent stem cells from somatic cells (tissue cells), "My current research focuses on ways to generate cells resembling embryonic stem cells by reprogramming somatic, or skin, cells. I was awarded the 2012 Nobel Prize in Physiology or Medicine for my discovery that adult somatic cells can be reprogrammed into pluripotent cells," claimed Yamanaka in his declaration. On the other hand, the first claim of Dr. Xu's organ regeneration application patent (US6991813) shows that human somatic cells, cultured in regenerative nutritional substances, can be converted in situ into pluripotent stem cells (keratin 19 expressing stem cells) and regenerate physiological tissues and organs in situ. This procedure has been accomplished in human use. Therefore, Dr. Xu has demonstrated that the human body has the innate regenerative potential to convert somatic cells into pluripotent stem cells; this regenerative potential is not created artificially.

(Photo: http://photos.prnewswire.com/prnh/20131009/LA94040)

On December 3, 2012, Dr. Xu sued the Nobel Assembly because of its false and misleading reporting has slandered Dr. Xu's reputation and the vendibility of his patents. Dr. Xu has also publically requested the Nobel Assembly to clarify whether the human regenerative potential by conversion into pluripotent stem cells is innate or created artificially by the Nobel prize winner. "Because this is a principle issue regarding the authenticity of life science and this point has to be clarified. This lawsuit is not only for my title to patent, but also for disclosing the truth of human regenerative potential on behalf of the public," said Dr. Xu, "In almost one year after my submission of the lawsuit against the Nobel Assembly, they have not yet had any response to aforementioned scientific principle issue. Instead, they have delayed the suit by removing the case to a federal court in the same area. In the meanwhile, they produced a documentary video covering the introduction of fake pluripotent stem cells and used it to further promote its misleading information on TV. In this period, my attorney informed me about the Nobel Assembly's invitation for a meeting to discuss the possibility of a settlement. While we would consider settlement as one of the options, because we just want to protect our rights by asking the Nobel Assembly to make a clarification on whether Yamanaka created a real pluripotent stem cell or fake pluripotent stem cell; we have no intention to undermine the reputation of the Nobel Assembly, but the filing of a suit was the only way which we could compel the Nobel Assembly to provide a response."

On May 8, 2013, Dr. Xu filed a lawsuit against Dr. Shinya Yamanaka, one of the winners of the 2012 Nobel Prize in Physiology or Medicine, for that the cell produced by Yamanaka using reprogramming method is a fake pluripotent stem cell, while Yamanaka named it "induced pluripotent stem cell (iPSC)" in his research and promote his fake pluripotent stem cell using the name and function of real pluripotent stem cell, do fraud with the name of iPSC. Therefore, Dr. Xu sued Yamanaka and asked the Court to grant a relief which would require Yamanaka to refrain from using the terms of real pluripotent stem cell or iPSC to describe his fake pluripotent stem cell.  Yamanaka acknowledged in his declaration that "If granted, this declaratory and injunctive relief would severely undermine my reputation in the scientific community, undermine our life-saving research, and cripple our ability to obtain funding for this research. The damage to my reputation, intellectual property, research, and income would certainly far exceed $75,000 if the relief requested by the Plaintiffs were granted."

From Dr. Xu's perspective, by employing the name of pluripotent stem cells both the Nobel Assembly and Dr. Yamanaka have committed false advertising. They do so to enhance the prestige of the prize and benefit from popularizing the fake pluripotent stem cell, respectively. Dr. Xu is steadfast in clarifying the defendants' conduct of false advertisements and unfair competition by continuous legal suits, no matter wherever they are and how many interest groups are involved, whereby to restore the authenticity and safety of scientific community.

About Dr. Rongxiang Xu

Dr. Rongxiang Xu is the founder of "Human Body Regenerative Restoration Science" (HBRRS), a renowned life scientist and medical scientist and chairman of the board of MEBO International, a California and Beijing based intellectual property Management Company responsible for managing HBRRS. Dr. Xu is also a standing Member of the Chinese Medical Doctor Association, and Honorable Chairman of the Chinese Burn Association of the Integration of Traditional and Western Medicine.

For more information on Dr. Xu, visit www.mebo-international.com

Contact:
Jane Westgate: 336-209-9276, [email protected]
Cheryl Riley: 703-683-1798, [email protected]

SOURCE Dr. Rongxiang Xu

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.